Novavax (NVAX) Set to Announce Quarterly Earnings on Friday

Novavax (NASDAQ:NVAX) is scheduled to issue its quarterly earnings data before the market opens on Friday, May 10th. Analysts expect the company to announce earnings of ($1.04) per share for the quarter. Novavax has set its Q1 2024 guidance at EPS and its FY 2024 guidance at EPS.Parties that wish to listen to the company’s conference call can do so using this link.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.95). The company had revenue of $291.34 million during the quarter, compared to analysts’ expectations of $310.96 million. Novavax’s revenue was down 18.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.28) EPS. On average, analysts expect Novavax to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Novavax Stock Performance

Shares of NVAX opened at $4.47 on Thursday. The firm has a market capitalization of $627.60 million, a price-to-earnings ratio of -0.81 and a beta of 1.63. Novavax has a one year low of $3.53 and a one year high of $11.36. The stock’s fifty day moving average is $4.67 and its 200-day moving average is $4.99.

Analyst Ratings Changes

Separately, HC Wainwright lowered their price target on Novavax from $35.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, March 1st.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.